{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:29:44Z","timestamp":1781645384957,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04155-7","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:53:12Z","timestamp":1772067192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of tumor treating fields on overall and progression-free survival in newly diagnosed glioblastoma: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Siddharth","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuraag","family":"Punukollu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saeed","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihit","family":"Kalawatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa Sabir","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Lucke-Wold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4155_CR1","unstructured":"Kanderi T, Munakomi S, Gupta V, Glioblastoma M (2024) May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558954\/"},{"key":"4155_CR2","doi-asserted-by":"publisher","unstructured":"Tamimi AF, Juweid M (2017) Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, (eds) Glioblastoma [Internet]. Brisbane (AU): Codon Publications. Chapter 8. https:\/\/doi.org\/10.15586\/codon.glioblastoma.2017.ch8","DOI":"10.15586\/codon.glioblastoma.2017.ch8"},{"issue":"1","key":"4155_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medsci12010001","volume":"12","author":"S Shah","year":"2023","unstructured":"Shah S (2023) Novel therapies in glioblastoma treatment: review of glioblastoma; current treatment options; and novel oncolytic viral therapies. Med Sci 12(1):1. https:\/\/doi.org\/10.3390\/medsci12010001","journal-title":"Med Sci"},{"key":"4155_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Dey D, Barik D et al (2025) Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Sig Transduct Target Ther 10:213. https:\/\/doi.org\/10.1038\/s41392-025-02299-4","journal-title":"Sig Transduct Target Ther"},{"issue":"11","key":"4155_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13111536","volume":"13","author":"RS Angom","year":"2023","unstructured":"Angom RS, Nakka NMR, Bhattacharya S (2023) Advances in glioblastoma therapy: an update on current approaches. Brain Sci 13(11):1536. https:\/\/doi.org\/10.3390\/brainsci13111536","journal-title":"Brain Sci"},{"issue":"10","key":"4155_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"11","key":"4155_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115694","volume":"25","author":"S Shah","year":"2024","unstructured":"Shah S, Mansour HM, Aguilar TM, Lucke-Wold B (2024) Advances in anti-cancer drug development: metformin as anti-angiogenic supplemental treatment for glioblastoma. Int J Mol Sci 25(11):5694. https:\/\/doi.org\/10.3390\/ijms25115694","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4155_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.5603\/RPOR.a2022.0113","volume":"27","author":"S Mohammed","year":"2022","unstructured":"Mohammed S, Dinesan M, Ajayakumar T (2022) Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother 27(6):1026\u20131036. https:\/\/doi.org\/10.5603\/RPOR.a2022.0113","journal-title":"Rep Pract Oncol Radiother"},{"issue":"8","key":"4155_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081927","volume":"10","author":"A Leone","year":"2022","unstructured":"Leone A, Colamaria A, Fochi NP, Sacco M, Landriscina M, Parbonetti G, de Notaris M, Coppola G, De Santis E, Giordano G et al (2022) Recurrent glioblastoma treatment: state of the art and future perspectives in the precision medicine era. Biomedicines 10(8):1927. https:\/\/doi.org\/10.3390\/biomedicines10081927","journal-title":"Biomedicines"},{"issue":"12","key":"4155_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122664","volume":"12","author":"S Shah","year":"2024","unstructured":"Shah S, Nag A, Sachithanandam SV, Lucke-Wold B (2024) Predictive and prognostic significance of molecular biomarkers in glioblastoma. Biomedicines 12(12):2664. https:\/\/doi.org\/10.3390\/biomedicines12122664","journal-title":"Biomedicines"},{"issue":"10","key":"4155_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/neuonc\/now182","volume":"18","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF, Pacheco P, Stupp R (2016) Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 18(10):1338\u20131349. https:\/\/doi.org\/10.1093\/neuonc\/now182","journal-title":"Neuro Oncol"},{"issue":"7","key":"4155_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071211","volume":"17","author":"RN Liu","year":"2025","unstructured":"Liu RN, Huang JH, Qi X, Pan Y, Wu E, Nizamutdinov D (2025) Tumor treating fields and combination therapy in management of brain oncology. Cancers (Basel) 17(7):1211. https:\/\/doi.org\/10.3390\/cancers17071211","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4155_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae227","volume":"30","author":"S Khagi","year":"2025","unstructured":"Khagi S, Kotecha R, Gatson NT, Jeyapalan S, Abdullah HI, Avgeropoulos NG, Batzianouli ET, Giladi M, Lustgarten L, Goldlust SA (2025) Recent advances in tumor treating fields (TTFields) therapy for glioblastoma. Oncologist 30(2):e227. https:\/\/doi.org\/10.1093\/oncolo\/oyae227","journal-title":"Oncologist"},{"issue":"7","key":"4155_CR14","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1007\/s12094-025-03849-6","volume":"27","author":"S Shah","year":"2025","unstructured":"Shah S, Nag A, Lucke-Wold B (2025) Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma. Clin Transl Oncol 27(7):2904\u20132912. https:\/\/doi.org\/10.1007\/s12094-025-03849-6","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"4155_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.brs.2025.07.018","volume":"18","author":"T Eckert","year":"2025","unstructured":"Eckert T, Suresh R, Zobaer MS, Rowland NC (2025) Invasive and non-invasive tumor-treating electric field (TTF) therapy: an exciting advance in oncologic neuromodulation. Brain Stimul 18(5):1357\u20131366. https:\/\/doi.org\/10.1016\/j.brs.2025.07.018","journal-title":"Brain Stimul"},{"issue":"17","key":"4155_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103016","volume":"12","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Schneiderman RS, Volodin A, Shamir RR, Kaynan N, Zeevi E, Koren L, Klein-Goldberg A, Paz R, Giladi M, Bomzon Z, Weinberg U, Palti Y (2020) Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers (Basel) 12(17):3016. https:\/\/doi.org\/10.3390\/cancers12103016","journal-title":"Cancers (Basel)"},{"key":"4155_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y (2015) Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5:18046. https:\/\/doi.org\/10.1038\/srep18046","journal-title":"Sci Rep"},{"issue":"12","key":"4155_CR18","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/ijc.30406","volume":"139","author":"T Voloshin","year":"2016","unstructured":"Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, Bomzon Z, Urman N, Itzhaki A, Cahal S, Kirson ED, Weinberg U, Palti Y (2016) Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer 139(12):2850\u20132858. https:\/\/doi.org\/10.1002\/ijc.30406","journal-title":"Int J Cancer"},{"key":"4155_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02861-0","volume":"16","author":"M Zang","year":"2025","unstructured":"Zang M, Zhu S, Niu Q (2025) Advancement in tumor treating fields of mechanism, clinical applications, and future directions. Discover Oncol 16:1049. https:\/\/doi.org\/10.1007\/s12672-025-02861-0","journal-title":"Discover Oncol"},{"issue":"20","key":"4155_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.171","volume":"8","author":"M Silginer","year":"2017","unstructured":"Silginer M, Weller M, Stupp R, Roth P (2017) Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis 8(20):e2753. https:\/\/doi.org\/10.1038\/cddis.2017.171","journal-title":"Cell Death Dis"},{"key":"4155_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocn.2016.10.042","volume":"36","author":"PA Clark","year":"2017","unstructured":"Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI (2017) The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. J Clin Neurosci 36:120\u2013124. https:\/\/doi.org\/10.1016\/j.jocn.2016.10.042","journal-title":"J Clin Neurosci"},{"issue":"17","key":"4155_CR22","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","volume":"82","author":"JC Moser","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, Swanson K, Tuszynski J, Carlson KW, Karanam NK, Patel CB, Story M, Lou E, Hagemann C (2022) The mechanisms of action of tumor treating fields. Cancer Res 82(17):3650\u20133658. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0887","journal-title":"Cancer Res"},{"issue":"9","key":"4155_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100708","volume":"6","author":"D Chen","year":"2025","unstructured":"Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O\u2019Dell A, Rahman M, Tran DD (2025) Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: a phase 2 study. Med 6(9):100708. https:\/\/doi.org\/10.1016\/j.medj.2025.100708","journal-title":"Med"},{"issue":"2","key":"4155_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071211","volume":"17","author":"RN Liu","year":"2025","unstructured":"Liu RN, Huang JH, Qi X, Pan Y, Wu E, Nizamutdinov D (2025) Tumor treating fields and combination therapy in management of brain oncology. Cancers (Basel) 17(2):1211. https:\/\/doi.org\/10.3390\/cancers17071211","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4155_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2478\/raon-2023-0044","volume":"57","author":"X Li","year":"2023","unstructured":"Li X, Liu K, Xing L, Rubinsky B (2023) A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights. Radiol Oncol 57(4):279\u2013291. https:\/\/doi.org\/10.2478\/raon-2023-0044","journal-title":"Radiol Oncol"},{"issue":"29","key":"4155_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372(29):n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"1","key":"4155_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-025-04946-w","volume":"173","author":"DC Riegel","year":"2025","unstructured":"Riegel DC, Bureau BL, Conlon P, Chavez G, Connelly JM (2025) Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting. J Neurooncol 173(1):49\u201357. https:\/\/doi.org\/10.1007\/s11060-025-04946-w","journal-title":"J Neurooncol"},{"issue":"2","key":"4155_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-025-04985-3","volume":"173","author":"PYM Woo","year":"2025","unstructured":"Woo PYM, Pu JKS, Li LF, Wong DKK, Hui VKH, Chan DTM, Lee MWY, Chan TKT, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, Ko NMW, Loong HHF, El-Helali A, Lam TC, Cheung FC, Poon WS (2025) Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study. J Neurooncol 173(2):317\u2013330. https:\/\/doi.org\/10.1007\/s11060-025-04985-3","journal-title":"J Neurooncol"},{"key":"4155_CR29","doi-asserted-by":"publisher","first-page":"111395","DOI":"10.1016\/j.jocn.2025.111395","volume":"138","author":"DJ Crompton","year":"2025","unstructured":"Crompton DJ, Kern S, Bogan A, Do B, Vora S, Quinones-Hinojosa A, Burns T, Sherman W, Sener UT, Porter AB, Brown P, Laack N, Story MD, Peterson J, Breen WG, Trifiletti DM (2025) Tumor treating fields utilization and efficacy for glioblastoma at a large multicenter academic practice. J Clin Neurosci 138:111395. https:\/\/doi.org\/10.1016\/j.jocn.2025.111395","journal-title":"J Clin Neurosci"},{"issue":"1","key":"4155_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae176","volume":"6","author":"M Kanamori","year":"2024","unstructured":"Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K, Yamaguchi S, Natsumeda M, Matsutani T, Hanihara M, Nakada M, Kuroda JI, Matsuda M, Yoshimoto K, Yonezawa U, Sonoda Y, Takano K, Yonezawa H, Otani Y, Nakahara Y, Uchida M, Nonaka M, Mineharu Y, Kitamura Y, Yamashita S, Yamauchi T, Miyake Y, Deguchi S, Beppu T, Tamura K, Koizumi S, Hirose Y, Asano K, Hiruta R, Kinoshita M, Miyake K, Nakayama N, Inoue A, Ono T, Sasaki T, Akiyama Y, Fukami S, Yoshino A, Kawanishi Y, Asanome T, Yamaguchi T, Takahashi M, Yamasaki F, Arakawa Y, Narita Y (2024) Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: a multicenter, retrospective cohort study. Neuro-Oncol Adv 6(1):vdae176. https:\/\/doi.org\/10.1093\/noajnl\/vdae176","journal-title":"Neuro-Oncol Adv"},{"issue":"11","key":"4155_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7350","volume":"13","author":"L Zhang","year":"2024","unstructured":"Zhang L, Ren Y, Peng Y, Luo Y, Liu Y, Wang X, Yang Y, Liu L, Ai P, Yang X, Li Y, Mao Q, Wang F (2024) Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: a retrospective analysis of Chinese patients in a single center. Cancer Med 13(11):e7350. https:\/\/doi.org\/10.1002\/cam4.7350","journal-title":"Cancer Med"},{"key":"4155_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1042888","volume":"13","author":"L She","year":"2023","unstructured":"She L, Gong X, Su L, Liu C (2023) Effectiveness and safety of tumor-treating fields therapy for glioblastoma: a single-center study in a Chinese cohort. Front Neurol 13:1042888. https:\/\/doi.org\/10.3389\/fneur.2022.1042888","journal-title":"Front Neurol"},{"key":"4155_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1014455","volume":"12","author":"J Vymazal","year":"2023","unstructured":"Vymazal J, Kazda T, Novak T, Slanina P, Sroubek J, Klener J, Hrbac T, Syrucek M, Rulseh AM (2023) Eighteen years\u2019 experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. Front Oncol 12:1014455. https:\/\/doi.org\/10.3389\/fonc.2022.1014455","journal-title":"Front Oncol"},{"issue":"1","key":"4155_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac096","volume":"4","author":"M Pandey","year":"2022","unstructured":"Pandey M, Xiu J, Mittal S, Zeng J, Saul M, Kesari S, Azadi A, Newton H, Deniz K, Ladner K, Sumrall A, Korn WM, Lou E (2022) Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncol Adv 4(1):vdac096. https:\/\/doi.org\/10.1093\/noajnl\/vdac096","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"4155_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac150","volume":"4","author":"MT Ballo","year":"2022","unstructured":"Ballo MT, Qualls KW, Michael LM, Sorenson JM, Baughman B, Karri-Wellikoff S, Pandey M (2022) Determinants of tumor treating field usage in patients with primary glioblastoma: a single institutional experience. Neuro-Oncol Adv 4(1):vdac150. https:\/\/doi.org\/10.1093\/noajnl\/vdac150","journal-title":"Neuro-Oncol Adv"},{"issue":"10","key":"4155_CR36","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.21873\/anticanres.14597","volume":"40","author":"Y Liu","year":"2020","unstructured":"Liu Y, Strawderman MS, Warren KT, Richardson M, Serventi JN, Mohile NA, Milano MT, Walter KA (2020) Clinical efficacy of tumor treating fields for newly diagnosed glioblastoma. Anticancer Res 40(10):5801\u20135806. https:\/\/doi.org\/10.21873\/anticanres.14597","journal-title":"Anticancer Res"},{"issue":"23","key":"4155_CR37","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"issue":"2","key":"4155_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","volume":"141","author":"SA Toms","year":"2019","unstructured":"Toms SA, Kim CY, Nicholas G, Ram Z (2019) Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol 141(2):467\u2013473. https:\/\/doi.org\/10.1007\/s11060-018-03057-z","journal-title":"J Neurooncol"},{"key":"4155_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671972","volume":"11","author":"Z Ram","year":"2021","unstructured":"Ram Z, Kim CY, Hottinger AF, Idbaih A, Nicholas G, Zhu JJ (2021) Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol 11:671972. https:\/\/doi.org\/10.3389\/fonc.2021.671972","journal-title":"Front Oncol"},{"issue":"3","key":"4155_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11060-019-03361-2","volume":"146","author":"CY Kim","year":"2020","unstructured":"Kim CY, Paek SH, Nam DH, Chang JH, Hong YK, Kim JH, Kim OL, Kim SH (2020) Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. J Neurooncol 146(3):399\u2013406. https:\/\/doi.org\/10.1007\/s11060-019-03361-2","journal-title":"J Neurooncol"},{"issue":"3","key":"4155_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-017-2601-y","volume":"135","author":"JJ Zhu","year":"2017","unstructured":"Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A, Ram Z (2017) Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 135(3):545\u2013552. https:\/\/doi.org\/10.1007\/s11060-017-2601-y","journal-title":"J Neurooncol"},{"issue":"1","key":"4155_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-023-04348-w","volume":"164","author":"MT Ballo","year":"2023","unstructured":"Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM (2023) Association of tumor treating fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. J Neurooncol 164(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-023-04348-w","journal-title":"J Neurooncol"},{"issue":"2","key":"4155_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.837","volume":"117","author":"MT Ballo","year":"2023","unstructured":"Ballo MT, Conlon P, Lavy-Shahaf G, Urman N, Kinzel A, Vymazal J, Rulseh AM (2023) Tumor treating fields (TTFields) for newly diagnosed glioblastoma in the real world: a systematic review and survival meta-analysis. Int J Radiat Oncol Biol Phys 117(2):e85. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.837","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4155_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/nop\/npab026","volume":"8","author":"O Regev","year":"2021","unstructured":"Regev O, Merkin V, Blumenthal DT, Melamed I, Kaisman-Elbaz T (2021) Tumor-treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neurooncol Pract 8(4):426\u2013440. https:\/\/doi.org\/10.1093\/nop\/npab026","journal-title":"Neurooncol Pract"},{"key":"4155_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-073753","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Wang J, Yuan G et al (2023) Efficacy of TTFields in high-grade gliomas: a protocol for systematic review and meta-analysis. BMJ Open 13:e073753. https:\/\/doi.org\/10.1136\/bmjopen-2023-073753","journal-title":"BMJ Open"},{"issue":"Suppl 3","key":"4155_CR46","doi-asserted-by":"publisher","first-page":"iii16","DOI":"10.1093\/neuonc\/noad147.067","volume":"25","author":"M Ballo","year":"2023","unstructured":"Ballo M, Conlon P, Lavy-Shahaf G, Urman MN, Kinzel A, Vyamzal J, Rulseh A (2023) Tumour treating fields (TTFIELDS) therapy in newly diagnosed glioblastoma: a meta-analysis and systematic review of real-world survival data. Neuro-Oncol 25(Suppl 3):iii16. https:\/\/doi.org\/10.1093\/neuonc\/noad147.067","journal-title":"Neuro-Oncol"},{"issue":"3","key":"4155_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2217\/cns-2016-0049","volume":"6","author":"S Kesari","year":"2017","unstructured":"Kesari S, Ram Z (2017) Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol 6(3):185\u2013193. https:\/\/doi.org\/10.2217\/cns-2016-0049","journal-title":"CNS Oncol"},{"issue":"4","key":"4155_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R (2018) Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(4):495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082","journal-title":"JAMA Oncol"},{"issue":"2","key":"4155_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/COC.0000000000000395","volume":"41","author":"SH Burri","year":"2018","unstructured":"Burri SH, Gondi V, Brown PD, Mehta MP (2018) The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists. Am J Clin Oncol 41(2):191\u2013196. https:\/\/doi.org\/10.1097\/COC.0000000000000395","journal-title":"Am J Clin Oncol"},{"issue":"48","key":"4155_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036421","volume":"102","author":"G Olatunji","year":"2023","unstructured":"Olatunji G, Aderinto N, Adefusi T, Kokori E, Akinmoju O, Yusuf I, Olusakin T, Muzammil MA (2023) Efficacy of tumour-treating fields therapy in recurrent glioblastoma: a narrative review of current evidence. Medicine (Baltimore) 102(48):e36421. https:\/\/doi.org\/10.1097\/MD.0000000000036421","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4155_CR51","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","volume":"24","author":"EJ Mun","year":"2018","unstructured":"Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD (2018) Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res 24(2):266\u2013275. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1117","journal-title":"Clin Cancer Res"},{"key":"4155_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-018-0079-9","volume":"4","author":"AF Kessler","year":"2018","unstructured":"Kessler AF, Fr\u00f6mbling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, L\u00f6hr M, Hagemann C (2018) Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov 4:12. https:\/\/doi.org\/10.1038\/s41420-018-0079-9","journal-title":"Cell Death Discov"},{"issue":"1","key":"4155_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01206-y","volume":"8","author":"G Tanzhu","year":"2022","unstructured":"Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D, Zhou R (2022) The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 8(1):416. https:\/\/doi.org\/10.1038\/s41420-022-01206-y","journal-title":"Cell Death Discov"},{"issue":"8","key":"4155_CR54","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1080\/09553002.2020.1837984","volume":"97","author":"NK Karanam","year":"2021","unstructured":"Karanam NK, Story MD (2021) An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol 97(8):1044\u20131054. https:\/\/doi.org\/10.1080\/09553002.2020.1837984","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"4155_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/14737159.2022.2017283","volume":"22","author":"P Hong","year":"2022","unstructured":"Hong P, Kudulaiti N, Wu S, Nie J, Zhuang D (2022) Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn 22(1):19\u201328. https:\/\/doi.org\/10.1080\/14737159.2022.2017283","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"4155_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2478\/raon-2023-0044","volume":"57","author":"X Li","year":"2023","unstructured":"Li X, Liu K, Xing L, Rubinsky B (2023) A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights. Radiol Oncol 57(3):279\u2013291. https:\/\/doi.org\/10.2478\/raon-2023-0044","journal-title":"Radiol Oncol"},{"issue":"23","key":"4155_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235642","volume":"15","author":"Y Lan","year":"2023","unstructured":"Lan Y, Zhang S, Pan Y, Wang M, Chen G (2023) Research progress on the mechanism of anti-tumor immune response induced by TTFields. Cancers (Basel) 15(23):5642. https:\/\/doi.org\/10.3390\/cancers15235642","journal-title":"Cancers (Basel)"},{"key":"4155_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1274587","volume":"13","author":"K Szklener","year":"2023","unstructured":"Szklener K, Bilski M, Nieoczym K, Ma\u0144dziuk D, Ma\u0144dziuk S (2023) Enhancing glioblastoma treatment through the integration of tumor-treating fields. Front Oncol 13:1274587. https:\/\/doi.org\/10.3389\/fonc.2023.1274587","journal-title":"Front Oncol"},{"issue":"2","key":"4155_CR59","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3171\/2016.9.JNS16452","volume":"128","author":"S Mittal","year":"2018","unstructured":"Mittal S, Klinger NV, Michelhaugh SK, Barger GR, Pannullo SC, Juh\u00e1sz C (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128(2):414\u2013421. https:\/\/doi.org\/10.3171\/2016.9.JNS16452","journal-title":"J Neurosurg"},{"issue":"10","key":"4155_CR60","first-page":"1543","volume":"68","author":"FA Mirza","year":"2018","unstructured":"Mirza FA, Shamim MS (2018) Tumour treating fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme. J Pak Med Assoc 68(10):1543\u20131545","journal-title":"J Pak Med Assoc"},{"key":"4155_CR61","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","volume":"124","author":"O Rominiyi","year":"2021","unstructured":"Rominiyi O, Vanderlinden A, Clenton SJ et al (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions. Br J Cancer 124:697\u2013709. https:\/\/doi.org\/10.1038\/s41416-020-01136-5","journal-title":"Br J Cancer"},{"issue":"11","key":"4155_CR62","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s00520-025-10085-9","volume":"33","author":"M Sadovnik","year":"2025","unstructured":"Sadovnik M, Zbidat S, Sellevoll M, Edelstein S, Lavy-Shahaf G, Blatt R, Tzchori I, Haber A, Giladi M, Weinberg U, Palti Y (2025) Testing the effects of topical skin care products on tumor treating fields (TTFields) adhesiveness of arrays and delivery of electric currents. Support Care Cancer 33(11):1008. https:\/\/doi.org\/10.1007\/s00520-025-10085-9","journal-title":"Support Care Cancer"},{"key":"4155_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00773-5","volume":"21","author":"AP Ghiaseddin","year":"2020","unstructured":"Ghiaseddin AP, Shin D, Melnick K et al (2020) Tumor treating fields in the management of patients with malignant gliomas. Curr Treat Options Oncol 21:76. https:\/\/doi.org\/10.1007\/s11864-020-00773-5","journal-title":"Curr Treat Options Oncol"},{"key":"4155_CR64","doi-asserted-by":"publisher","unstructured":"Wang L, Xiao Y, Chen C, Fu X, Gong R, Shen J, Lu M (2025) A theoretical study of dielectrophoretic effects on septins during cytokinesis under tumor treating fields. Comput Methods Biomech Biomed Engin. 1\u201316. https:\/\/doi.org\/10.1080\/10255842.2025.2578322","DOI":"10.1080\/10255842.2025.2578322"},{"issue":"5","key":"4155_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14720","volume":"30","author":"J Lan","year":"2024","unstructured":"Lan J, Liu Y, Chen J, Liu H, Feng Y, Liu J, Chen L (2024) Advanced tumor electric fields therapy: a review of innovative research and development and prospect of application in glioblastoma. CNS Neurosci Ther 30(5):e14720. https:\/\/doi.org\/10.1111\/cns.14720","journal-title":"CNS Neurosci Ther"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04155-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:53:22Z","timestamp":1772067202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4155"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04155-7","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"None. The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial interests"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}